Condition Directory

Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Cancer. Browse Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

50397

Shown on this page

Current sort

How Cancer studies are organized in the registry

“Cancer” is the broadest term in the registry, and most oncology records list a specific cancer type rather than the umbrella word. If you are researching a particular diagnosis, the dedicated pages for that cancer type usually give a cleaner result set. Tumor-agnostic and basket studies are the exception — they often appear under generic terms instead of a single organ site.

Terms that often appear in related listings

solid tumor advanced solid tumors metastatic basket trial

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1045–1056 of 50,397 matching trials for Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Small Cell Lung Cancer ( SCLC )
Interventions: Alisertib, Paclitaxel; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions: Metarrestin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Fairway, Kansas • Bethesda, Maryland

Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Local Disease
Interventions: Lumason, Contrast-Enhanced Ultrasound; Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Hypercortisolemia, Cushing Syndrome
Interventions: Osilodrostat, Placebo; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Jacksonville, Florida • Canton, Ohio • Weslaco, Texas

Conditions: Lung Cancer
Interventions: AMG 510, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 92
States / cities: Irvine, California • Los Angeles, California • Newport Beach, California + 72 more

Conditions: Urothelial Cancer
Interventions: Nivolumab, Ipilimumab, Gemcitabine, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 29
States / cities: Anchorage, Alaska • Fresno, California • Santa Rosa, California + 24 more

Conditions: Muscle-invasive Bladder Cancer
Interventions: Enfortumab Vedotin, Pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 19
States / cities: Little Rock, Arkansas • Stanford, California • Chicago, Illinois + 16 more

Conditions: Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan; Drug · Diagnostic Test
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 40 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Solid Tumors
Interventions: Asciminib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Digital Rectal Examination, High Resolution Anoscopy, Magnetic Resonance Imaging, Nivolumab, Patient Observation, Proctoscopy, Sigmoidoscopy, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 887
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 568 more

Conditions: Hodgkin Lymphoma
Interventions: Ruxolitinib, Nivolumab; Drug
Lead sponsor: Veronika Bachanova; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 6
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 3 more

About this Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cancer clinical trials

How Cancer studies are organized in the registry

Filter and sort this condition

Live official records

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

About this Cancer clinical trials directory page